Fulcrum Therapeutics, a clinical-stage biotech developing therapies based on gene regulation for rare diseases, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The Cambridge, MA-based company was founded in 2016 and it plans to list on the Nasdaq under the symbol FULC. It had been on our Private Company Watchlist since September 2018. Morgan Stanley, BofA Merrill Lynch and SVB Leerink are the joint bookrunners on the deal. No pricing terms were disclosed.
